Применение Антитромбина-III при новой коронавирусной инфекции (Covid-19) в условиях экстракорпоральной мембранной оксигенации (клиническое наблюдение)

COVID-19 является заболеванием, приводящим помимо дыхательной недостаточности к тромбозам и кровотечениям вследствие нарушений в системе гемостаза. Экстракорпоральная мембранная оксигенация (ЭКМО), требующаяся при снижении газообменной функции легких, вносит свой вклад в изменения показателей свертывания крови, что ведет к увеличению риска осложнений геморрагического характера и тромбозов. В статье представлен клинический случай тяжелого течения COVID-19, потребовавший проведения ЭКМО. В ходе лечения был использован Антитромбин-III, что позволило избежать жизнеугрожающих осложнений и успешно завершить процедуру. 

1. Журавель С.В., Евсеев А.К., Колокольцев А.Д., Кузнецова Н.К., Уткина И.И., Петриков С.С. Историческое развитие и перспективы экстракорпоральной мембранной оксигенации в клинической практике. Высокотехнологичная медицина. 2020;7(1):51–58.

2. Брыгин П.А., Журавель С.В., Троицкий Д.А., Уткина И.И. Предикторы эффективности применения экстракорпоральной мембранной оксигенации при острой дыхательной недостаточности. Трансплантология. 2020;12(3):220–230. https://doi.org/10.23873/2074-0506-2020-12-3-220-230

3. Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO J. 2020;66(5):472–474. PMID: 32243267 https://doi.org/10.1097/MAT.0000000000001173

4. Badulak J, Antonini MV, Stead CM, Shekerdemian L, Raman L, Paden ML, ECMO for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021 Feb 26. PMID: 33657573 https://doi.org/10.1097/MAT.0000000000001422. Online ahead of print.

5. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. PMID: 32291094 https://doi.org/10.1016/j.thromres.2020.04.013

6. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500. PMID: 32492712 https://doi.org/10.1182/blood.2020006520

7. Chang JC. Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: Pathogenesis based on “two activation theory of the endothelium”. Vascul Dis Ther. 2017;2(5):1–7. https://doi.org/10.15761/VDT.1000132

8. Pravda NS, Pravda MS, Kornowski R, Orvin K. Extracorporeal membrane oxygenation therapy in the COVID-19 pandemic. Future Cardiol. 2020;16(6):543–546. PMID: 32301347 https://doi.org/10.2217/fca2020-0040

9. Smereka J, Puslecki M, Ruetzler K, Filipiak KJ, Jaguszewski M, Ladny JR, et al. Extracorporeal membrane oxygenation in COVID-19. Cardiol J. 2020;27(2):216–217. PMID: 32285929 https://doi.org/10.5603/CJ.a2020.0053

10. Jacobs JP, Stammers AH, St Louis J, Hayanga JWA, Firstenberg MS, Mongero LB, et al. Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients. ASAIO J. 2020;66(7):722– 730. PMID: 32317557 https://doi.org/ 10.1097/MAT.0000000000001185

11. Ziats NP, Pankowsky DA, Tierney BP, Ratnoff OD, Anderson JM. Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers. J Lab Clin Med. 1990;116(5):687–696. PMID: 2146350

12. Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72(5):S1821–1831. PMID: 11722116 https://doi.org/10.1016/s0003-4975(01)03211-8

13. Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020; 3(3):CD012467. PMID: 32164041 https://doi.org/10.1002/14651858.CD012467.pub2

14. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–1561. PMID: 32302453 https://doi.org/10.1111/jth.14849

15. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747– 1751. PMID: 32302448 https://doi.org/10.1111/jth.14854

16. Mulder M, Fawzy I, Lance M. ECMO and anticoagulation: a comprehensive review. Neth J Crit Care. 2018;26(1):6–13.

17. Protti A, Iapichino GE, Di Nardo M, Panigada M, Gattinoni L. Anticoagulation Management and Antithrombin Supplementation Practice during Veno-venous Extracorporeal Membrane Oxygenation: A Worldwide Survey. Anesthesiology. 2020;132(3):562–570. PMID: 31764152 https://doi.org/10.1097/ALN.0000000000003044

18. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49–56. PMID: 8267489

19. Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. J Thromb Thrombolysis. 2012;34(1):132–134. PMID: 22302637 https://doi.org/10.1007/s11239-012-0692-z

20. Downie I, Liederman Z, Thiyagarajah K, Selby R, Lin Y. Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient. Can J Anaesth. 2019;66(8):995–996. PMID: 31076959 https://doi.org/10.1007/s12630-019-01391-y

21. Durrani J, Malik F, Ali N, Jafri SIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8(3):145–148. PMID: 29915655 https://doi.org/10.1080/20009666.2018.1466599

22. Iapichino GE, Protti A, Andreis DT, Panigada M, Artoni A, Novembrino C, et al. Antithrombin during extracorporeal membrane oxygenation in adults: National survey and retrospective analysis. ASAIO J. 2019;65(3):257–263. PMID: 29746315 https://doi.org/10.1097/MAT.0000000000000806

23. Wong TE, Nguyen T, Shah SS, Brogan TV, Witmer CM. Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: A multicenter cohort study. Pediatr Crit Care Med. 2016;17(12):1170– 1178. PMID: 27662567 https://doi.org/10.1097/PCC.0000000000000955

24. Makdisi G, Wang I. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7(7): E166–E176. PMID: 26380745 https://doi.org/10.3978/j.issn.2072-1439.2015.07.17

25. Morales-Quinteros L, Del Sorbo L, Artigas A. Extracorporeal carbon dioxide removal for acute hypercapnic respiratory failure. Ann Intensive Care. 2019;9(1):79. PMID: 31267300 https://doi.org/10.1186/s13613-019-0551-6

26. Bilen O, Loftis L, Teruya J. Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol. 2011;43(2):64–69. PMID: 21848174

27. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–2973. PMID: https://doi.org/10.1016/j.jacc.2020.04.031

28. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: antiinflammatory properties and clinical applications. Thromb Haemostasis. 2016;115(4):712–728. PMID: 26676884 https://doi.org/10.1160/TH15- 08-0687